Yassine Fayez, Najm Adam, Bilen Melhem
Department of Experimental Pathology, Immunology, and Microbiology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon.
Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Front Syst Biol. 2025 Apr 16;5:1561047. doi: 10.3389/fsysb.2025.1561047. eCollection 2025.
The increasing incidence of inflammatory bowel diseases (IBD) over the last two decades has prompted the need to create new types of therapeutic interventions. The gut microbiome has emerged as a key component in the prognosis and pathophysiology of IBDs. The alteration or dysbiosis of the gut microbiome has been shown to exacerbate IBDs. The bacterial composition of the gut microbiome can be modulated through the usage of probiotics, prebiotics, and synbiotics. These interventions induce the growth of beneficial bacteria. Additionally, these interventions could be used to maintain gut homeostasis, reduce the inflammation seen in these morbidities, and strengthen the gut epithelial barrier.
The literature review was conducted in October 2024 using PubMed, Scopus, and Google Scholar screening for recent clinical trials in addition to reviews relevant to the topic.
This review aims to summarize the recent clinical trials of probiotics, prebiotics, and synbiotics in IBD patients highlighting their potential benefits in alleviating symptoms and enhancing the quality of life.
Certain probiotic formulations such as single strain ones consisting of or mixed-strain combinations of and , prebiotic compounds such as fructooligosaccharides, and synbiotic combinations of both have proven effective in improving the clinical, immunological, and symptomatic aspects of the disease course. While promising, these findings remain inconclusive due to inconsistent study designs, small sample sizes, and varying patient responses. This emphasizes the need for larger, well-controlled trials to determine their clinical efficacy.
在过去二十年中，炎症性肠病（IBD）的发病率不断上升，这促使人们需要开发新型治疗干预措施。肠道微生物群已成为IBD预后和病理生理学的关键组成部分。肠道微生物群的改变或失调已被证明会加剧IBD。肠道微生物群的细菌组成可以通过使用益生菌、益生元及合生元来调节。这些干预措施可促进有益细菌的生长。此外，这些干预措施可用于维持肠道稳态、减轻这些疾病中的炎症并加强肠道上皮屏障。
2024年10月进行了文献综述，除了筛选与该主题相关的综述外，还使用PubMed、Scopus和谷歌学术搜索近期的临床试验。
本综述旨在总结益生菌、益生元及合生元在IBD患者中的近期临床试验，突出它们在缓解症状和提高生活质量方面的潜在益处。
某些益生菌制剂，如由[具体菌株]组成的单一菌株制剂或[具体菌株]的混合菌株组合、益生元化合物如低聚果糖，以及两者的合生元组合，已被证明在改善疾病进程的临床、免疫和症状方面有效。尽管前景广阔，但由于研究设计不一致、样本量小以及患者反应各异，这些发现仍无定论。这强调了需要进行更大规模、严格对照的试验来确定它们的临床疗效。
